{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["3(4)"],"submitter":["Lam MA"],"pubmed_abstract":["<h4>Objective</h4>We aimed to investigate the role of oxidative stress in the progression of multiple sclerosis (MS).<h4>Methods</h4>We determined by liquid chromatography-tandem mass spectrometry nonenzymatic (F2-isoprostanes) and enzymatic oxidation products of arachidonic acid (prostaglandin F2α [PGF2α]) in plasma and CSF of 45 controls (other neurologic disease [OND] with no signs of inflammation) and 62 patients with MS. Oxidation products were correlated with disease severity and validated biomarkers of inflammation (chemokine ligand 13; matrix metalloproteinase-9; osteopontin) and axonal damage (neurofilament light protein).<h4>Results</h4>Compared with OND controls, plasma concentrations of F2-isoprostanes and PGF2α were significantly lower in patients with progressive disease, and"],"journal":["Neurology(R) neuroimmunology & neuroinflammation"],"pagination":["e256"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4929888"],"repository":["biostudies-literature"],"pubmed_title":["Absence of systemic oxidative stress and increased CSF prostaglandin F2α in progressive MS."],"pmcid":["PMC4929888"],"pubmed_authors":["Sellebjerg FT","Ratzer R","Olsson T","Khademi M","Lam MA","Romme Christensen J","Piehl F","Stocker R","Maghzal GJ"],"additional_accession":[]},"is_claimable":false,"name":"Absence of systemic oxidative stress and increased CSF prostaglandin F2α in progressive MS.","description":"<h4>Objective</h4>We aimed to investigate the role of oxidative stress in the progression of multiple sclerosis (MS).<h4>Methods</h4>We determined by liquid chromatography-tandem mass spectrometry nonenzymatic (F2-isoprostanes) and enzymatic oxidation products of arachidonic acid (prostaglandin F2α [PGF2α]) in plasma and CSF of 45 controls (other neurologic disease [OND] with no signs of inflammation) and 62 patients with MS. Oxidation products were correlated with disease severity and validated biomarkers of inflammation (chemokine ligand 13; matrix metalloproteinase-9; osteopontin) and axonal damage (neurofilament light protein).<h4>Results</h4>Compared with OND controls, plasma concentrations of F2-isoprostanes and PGF2α were significantly lower in patients with progressive disease, and","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016 Aug","modification":"2025-04-18T19:45:36.38Z","creation":"2019-03-27T02:17:21Z"},"accession":"S-EPMC4929888","cross_references":{"pubmed":["27386506"],"doi":["10.1212/NXI.0000000000000256"]}}